Who is eligible for clinical trial NCT06425302?

Participants must meet the protocol's inclusion criteria for Lymphoma, Follicular. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06425302 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-30

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (NCT06425302)

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Celgene

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (5 items).

Location: Local Institution - 0152 — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis.
Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable.
Stage II to IV disease.
Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:. i) Bulky disease defined as:. A. A nodal or extra nodal (except spleen) mass \> 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than \>3 cm). ii) Presence of at least one of the following B symptoms:. A. Fever (\>38°C) of unclear etiology. B. Night sweats. C. Weight loss greater than 10% within the prior 6 months. iii) Splenomegaly with inferior margin below the umbilical line. iv) Any one of the following cytopenia due to lymphoma:. A. Platelets \<100,000 cells/mm3 (100 x 109/L). B. Absolute neutrophil count (ANC) \< 1,000 cells/mm3 (1.0 x 109/L). C. Hemoglobin \< 10g/dL (6.25 mmol/L). v) Pleural or peritoneal serous effusion (irrespective of cell content). vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal).

Usually NOT eligible if any of the following apply:

Exclusion Criteria
Clinical evidence of transformed lymphoma by investigator assessment.
Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification.
Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study.
Other protocol-defined Inclusion/Exclusion criteria apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (56 Sites)

Showing the first 25 of 56 sites.

Local Institution - 0152 — Birmingham, Alabama
Local Institution - 0055 — Anchorage, Alaska
Local Institution - 0180 — Phoenix, Arizona
Local Institution - 0190 — Tucson, Arizona
Local Institution - 0035 — San Francisco, California
Local Institution - 0022 — Washington D.C., District of Columbia
Local Institution - 0209 — Fort Myers, Florida
Local Institution - 0005 — Jacksonville, Florida
Local Institution - 0210 — St. Petersburg, Florida
Local Institution - 0026 — Tampa, Florida
Local Institution - 0208 — West Palm Beach, Florida
Local Institution - 0019 — Westwood, Kansas
Local Institution - 0031 — Rochester, Minnesota
Local Institution - 0111 — Henderson, Nevada
Local Institution - 0183 — Hackensack, New Jersey
Local Institution - 0052 — Salt Lake City, Utah
Local Institution - 0201 — Norfolk, Virginia
Local Institution - 0202 — Seattle, Washington
Local Institution - 0046 — Liverpool, New South Wales
Local Institution - 0070 — South Brisbane, Queensland
Local Institution - 0181 — Traralgon, Victoria
Local Institution - 0061 — Porto Alegre, Rio Grande do Sul
Local Institution - 0060 — Rio de Janeiro,
Local Institution - 0058 — São Paulo,
Local Institution - 0056 — São Paulo,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma, Follicular

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells — Palo Alto, California
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma — St Louis, Missouri

Explore by condition: All Lymphoma, Follicular clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗